Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Dichotomies, such as reconstructive vs aesthetic surgery and medical vs cosmetic dermatology, can distort meanings of surgical procedures. This can compromise the value of procedures themselves and practices for their reimbursement.
AMA J Ethics. 2018;20(12):E1188-1194. doi:
10.1001/amajethics.2018.1188.
Women who are pregnant might not treat their mental illnesses because they overestimate risks of medication and underestimate risks of leaving their illness untreated.
AMA J Ethics. 2016;18(6):614-623. doi:
10.1001/journalofethics.2016.18.6.stas1-1606.
John is one patient-sitter whose cancer and portraiture experiences illuminate what it means to witness, to express regard for another’s difficult health and health care experiences.
AMA J Ethics. 2020;22(6):E470-475. doi:
10.1001/amajethics.2020.470.